Department of Physiology, All India Institute of Medical Sciences, Bibinagar, Telangana, India.
Department of Physiology, RVM Medical College, Siddipet, Hyderabad, Telangana, India.
Horm Mol Biol Clin Investig. 2024 Apr 17;45(2):49-53. doi: 10.1515/hmbci-2023-0088. eCollection 2024 Jun 1.
The emergence of the SARS-CoV-2 Omicron variant, classified as a Variant of Concern (VoC) in November 2021, marked a significant shift in the COVID-19 landscape. This study investigates the subsequent development of a novel Omicron sublineage, JN.1, which displays distinctive mutations in the spike protein. The study delves into the phylogenetic differences between these variants and their potential implications. A comprehensive analysis of the genomic profiles and mutation patterns of JN.1 and BA.2.86 was conducted, utilizing SARS-CoV-2 database. The study explores the unique mutations, such as S:L455S in JN.1, associated with increased transmissibility and immune escape. Furthermore, a comparison with prevalent strains like XBB.1.5 and HV.1 highlights the substantial genetic divergence of JN.1. JN.1, first detected in August 2023, exhibits a notable spike protein mutation profile, including the reappearance of earlier variants' mutations (E484K and P681R). The variant's increased transmissibility and immune evasion potential are attributed to specific spike protein mutations like R21T, S50L, V127F, R158G, and others. The study also explores the distribution and prevalence of JN.1 globally, with a focus on the rising cases in India. JN.1 poses a unique challenge as one of the most immune-evading variants, with potential implications for COVID-19 transmission. The study emphasizes the importance of monitoring and understanding emerging variants, especially those with distinct spike protein mutations. The observed cases in India highlight the need for vigilance and prompt public health responses. As JN.1 continues to evolve, ongoing surveillance, vaccination strategies, and adherence to preventive measures are crucial to mitigating its potential impact on global public health.
SARS-CoV-2 奥密克戎变异株的出现,于 2021 年 11 月被归类为关注变异株(VOC),标志着 COVID-19 形势的重大转变。本研究调查了随后出现的新型奥密克戎亚谱系 JN.1,其在刺突蛋白上显示出独特的突变。该研究深入探讨了这些变体之间的系统发育差异及其潜在影响。利用 SARS-CoV-2 数据库,对 JN.1 和 BA.2.86 的基因组特征和突变模式进行了全面分析。该研究探讨了与传播力和免疫逃逸增加相关的独特突变,如 JN.1 中的 S:L455S。此外,与 XBB.1.5 和 HV.1 等流行株的比较突出了 JN.1 的显著遗传差异。JN.1 于 2023 年 8 月首次检测到,其刺突蛋白突变谱显著,包括先前变异株突变(E484K 和 P681R)的再次出现。该变体的传播力增加和免疫逃逸潜力归因于特定的刺突蛋白突变,如 R21T、S50L、V127F、R158G 等。该研究还探讨了 JN.1 在全球的分布和流行情况,重点关注印度不断增加的病例。JN.1 作为最具免疫逃逸能力的变体之一,对 COVID-19 传播构成了独特的挑战。该研究强调了监测和理解新兴变体的重要性,特别是那些具有明显刺突蛋白突变的变体。印度观察到的病例突出表明需要保持警惕并采取迅速的公共卫生应对措施。随着 JN.1 的不断演变,持续监测、疫苗接种策略和遵守预防措施对于减轻其对全球公共卫生的潜在影响至关重要。